All In Biotech

Drug Trial Radar · NCT05909488

Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II

Role of Umbilical Cord-derived Stem Cell Transplantation and Conditioned Medium to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II

Last checked: Nov 20, 2026Latest source record: Feb 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

May 2026

Primary completion

Jul 2027

Study completion Sep 2027

Sponsor

Lead sponsor
PT. Prodia Stem Cell IndonesiaIndustry
Sponsor type
Industry
First posted
Jun 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will perform UC-MSCs and CM transplantation. There are two groups with different dosages. The first group will be transplanted with 1.5 million cells, meanwhile, the second group is 5 million cells. Each group consists of 30 subjects. All groups will be transplanted via the peribulbar route. All groups will be observed until six months.

Conditions

  • Retinitis Pigmentosa

Interventions

  • 1.5 x 10^6 UC-MSC + CMBiological

    1.5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)

  • 5 x 10^6 UC-MSC + CMBiological

    5 million cells of UC-MSC in 2 ml of Conditioned Medium (CM)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incident of Adverse EventsTime frame: 1 day after injection
  2. Incident of Adverse EventsTime frame: 1 week after injection
  3. Frequency of Adverse EventsTime frame: 1 day after injection
  4. Frequency of Adverse EventsTime frame: 1 week after injection
  5. Visual Acuity TestTime frame: 1 week after injection
  6. Visual Acuity TestTime frame: 1 month after injection
  7. Visual Acuity TestTime frame: 3 months after injection
  8. Visual Acuity TestTime frame: 6 months after injection
  9. Visual Field TestTime frame: 1 week after injection
  10. Visual Field TestTime frame: 1 month after injection
  11. Visual Field TestTime frame: 3 months after injection
  12. Visual Field TestTime frame: 6 months after injection
  13. FunduscopyTime frame: 1 week after injection
  14. FunduscopyTime frame: 1 month after injection
  15. FunduscopyTime frame: 3 months after injection
  16. FunduscopyTime frame: 6 months after injection
  17. ElectrorectinographyTime frame: 1 week after injection
  18. ElectrorectinographyTime frame: 1 month after injection
  19. ElectrorectinographyTime frame: 3 months after injection
  20. ElectrorectinographyTime frame: 6 months after injection
  21. Optical Coherence Tomography (OCT)Time frame: 1 week after injection
  22. Optical Coherence Tomography (OCT)Time frame: 1 month after injection
  23. Optical Coherence Tomography (OCT)Time frame: 3 months after injection
  24. Optical Coherence Tomography (OCT)Time frame: 6 months after injection

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • RSUP Dr. Sardjito

    Yogyakarta, DI Yogyakarta, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.